Psychedelic Business Spotlight: October 8, 2021
Business, Stock Reports
This week in psychedelic business news: Enveric Biosciences uses AI to identify viable psychedelic drug candidates; Novamind launches end-of-life palliative care program; and PharmaTher tests ketamine to treat Parkinson's Disease.
Suicide “behavior” or suicide “thoughts?.” There is a difference.
I’d love for someone to study how to help people on the bipolar spectrum with psilocybin. I am bipolar 2, and when I’m in a rage phase, mushrooms help me calm down. It would be great for severe PMS, and PTSD as well.
Interesting findings in this study, but the scope seems very limited.
There is no mention anywhere of any type of integration work being done by any of the patients, leaving the psychedelic experiences to be “just a trip”. It does not seem surprising then that most patients fall back to depressed/suicidal thoughts.
Any thoughts on this?
One session is not as good as the 3-session experiments published before…
Who know that if you return from your psychedelic trip to an ever-warming corporate capitalist neon-commercial hellscape, that you would get depressed again after 12 weeks, huh?